Developer docs
API playgroundTry for free, no card

Search company profiles

Bebetter Med

Full company profile

uuid0000qft

Namestring
Bebetter Med
Legal namestring
Guangzhou BeBetter Medical Pharmaceutical Co., Ltd. (广州必贝特医药股份有限公司)
Websiteurl
bebettermed.cn
Company typeenum
Public
Founded yearint
2012
Descriptiontext

BeBetter Med (Guangzhou BeBetter Medical Pharmaceutical Co., Ltd.) is a China-headquartered clinical-stage biopharmaceutical company founded in 2012 that designs first-in-class therapeutics across oncology, cardiometabolic disease, CNS, and kidney indications. Its portfolio is organized around four proprietary technology platforms: a Targeted Small Molecule platform that uses dual pharmacophore chemistry to build dual-target inhibitors; a GDOC platform for liver-targeted dual siRNA; a POC-Nervous System platform for CNS and peripheral nervous system delivery via peptide-oligonucleotide conjugates; and a POC-Kidney platform for renal tubular epithelial cell targeting. The most advanced commercial asset is Ifupinostat (BEBT-908), a globally first-in-class HDAC/PI3Kα dual-target inhibitor that received NMPA approval on July 2, 2025 for relapsed/refractory diffuse large B-cell lymphoma and has subsequently been included in the CSCO and Chinese national lymphoma guidelines (2026 edition). The pipeline additionally includes BEBT-209 (highly selective CDK4 inhibitor in seamless Phase IIb/III for mTNBC), BEBT-109 (EGFR exon 20 selective inhibitor in NSCLC), BEBT-701 (AGT/PCSK9 dual siRNA with both NMPA and FDA clearance), BEBT-503 (pan-PPAR agonist for MASH), and preclinical assets spanning Parkinson's, Alzheimer's, gout, and renal anemia.

The company monetizes via two complementary streams: domestic pharmaceutical product sales through hospital and specialty pharmacy channels in China following NMPA approval, and out-licensing or regional partnership arrangements with global pharma counterparties (revenue mechanics governed by milestone payments and royalties under flexible deal structures). Pricing is determined through Chinese government reimbursement and institutional procurement rather than public list pricing. The company went public on the Shanghai Stock Exchange STAR Market on October 28, 2025 under ticker 688759 and operates a wholly-owned US subsidiary, BeBetter Pharma Inc., in Waltham, Massachusetts to drive global clinical development and BD activity. BeBetter Med is presently organized with 51–100 employees and an active commercial team build-out in Beijing, Shanghai, and Guangzhou.

Short descriptiontext

BeBetter Med is a Guangzhou-based biopharmaceutical company (SSE STAR: 688759) developing first-in-class small molecule and dual siRNA therapeutics across oncology, cardiometabolic, CNS, and kidney diseases, with one approved product (Ifupinostat for r/r DLBCL) and a 14+ candidate pipeline spanning four proprietary technology platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule drugs, oncology therapeutics, siRNA drug development, dual-target inhibitors, oligonucleotide conjugates
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sale of approved drugs, including Ifupinostat (BEBT-908, marketed as 贝特琳®) which received NMPA approval in July 2025 for r/r DLBCL treatment

bebettermed.cn
2Licensing and Partnership Deals
TypeLicensing Royalties
Description

Revenue from out-licensing proprietary technologies and drug candidates to global pharmaceutical partners for clinical development and commercialization

bebettermed.cn
3Strategic Partnerships
TypeLicensing Royalties
Description

Revenue potential from collaborative development arrangements including co-development, option agreements, and regional partnerships for cardiovascular metabolism, oncology, CNS, and kidney disease programs

bebettermed.cn
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bebetter Med is a biopharmaceutical company that discovers, develops, and commercializes first-in-class dual-target small molecule drugs and oligonucleotide therapeutics (dual siRNA and peptide-oligonucleotide conjugates) for oncology, cardiovascular-metabolic diseases, CNS, and kidney diseases. The company sells its approved drug Ifupinostat (BEBT-908) for relapsed/refractory DLBCL in China and pursues out-licensing/co-development partnerships for global commercialization of its pipeline assets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Ifupinostat (BEBT-908) achieved 54.6% ORR in 3rd line+ and 76.2% ORR in 2nd line+ r/r DLBCL patients
+3 more records
Product overview1 text field

BeBetter Med is a biopharmaceutical company (SSE Stock: 688759) specializing in pioneering research and differentiated technology pathways focused on small molecule drugs and oligonucleotide conjugates. The company's portfolio consists of four integrated technology platforms: Targeted Small Molecule Drugs (for oncology and metabolic diseases), GDOC Platform (liver-targeting dual siRNA for cardiovascular metabolic conditions), POC-Nervous System Platform (CNS and peripheral delivery), and POC-Kidney Platform (renal tubular epithelial cell targeting). The pipeline includes 14+ clinical/preclinical candidates across oncology (BEBT-908/Ifupinostat, BEBT-209, BEBT-109), cardiovascular metabolic diseases (BEBT-701, BEBT-706, BEBT-720, BEBT-503, BEBT-809), and kidney/CNS diseases (BEBT-507, BEBT-758, BEBT-756, BEBT-730, BEBT-733, BEBT-738). Ifupinostat (BEBT-908) is the company's first approved drug (NMPA approved July 2025) as a global first-in-class HDAC/PI3Kα dual-target inhibitor for r/r DLBCL.

Product and service11 records
1Ifupinostat (BEBT-908 / 贝特琳®)
CategorySmall Molecule Oncology Drug (HDAC/PI3Kα Dual-Target Inhibitor)
Description

Global first-in-class HDAC/PI3Kα dual-target small molecule inhibitor approved in China for adult patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) who have received at least two prior lines of systemic therapy. Also in clinical development in combination with CHOP for peripheral T-cell lymphoma (PTCL). Reported 3L+ ORR 54.6% and 2L+ ORR 76.2% with favorable safety.

2BEBT-209
CategorySmall Molecule Oncology Drug (Selective CDK4 Inhibitor)
Description

Highly selective CDK4 inhibitor (CDK4 activity ~6x higher than CDK6) in Phase IIb/III seamless pivotal design for metastatic triple-negative breast cancer (mTNBC) and HR+/HER2- advanced breast cancer. Reported 2-3L ORR 37.5% and median PFS of 6.8 months with manageable safety in mTNBC.

3BEBT-109
CategorySmall Molecule Oncology Drug (Selective EGFR Exon 20 Inhibitor)
Description

Selective small molecule EGFR inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC). Phase Ib/II data presented at ESMO Asia 2025 showed 2L+ ORR 38.5% and median PFS of 8.9 months.

4BEBT-503
CategorySmall Molecule Metabolic Disease Drug (Pan-PPAR Agonist)
Description

Pan-PPAR agonist small molecule that completed Phase I clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and diabetes.

5BEBT-809
CategorySmall Molecule Metabolic Disease Drug (20-HETE/GPR75 Dual Inhibitor)
Description

Potential first-in-class 20-HETE/GPR75 dual-target small molecule inhibitor in preclinical stage for obesity treatment, designed to preserve muscle mass.

6BEBT-507
CategorysiRNA Therapeutic (Liver-Targeted Single siRNA)
Description

Liver-targeted single siRNA therapeutic targeting TMPRSS6 in Phase I clinical development for the treatment of polycythemia vera (PV).

7BEBT-701 (GDOC Dual siRNA)
CategorysiRNA Therapeutic (Liver-Targeted Dual siRNA — GDOC Platform)
Description

Global first-in-class AGT/PCSK9 dual-target siRNA drug built on the GDOC platform in Phase I/II clinical development for the treatment of hypertension and hyperlipidemia. Received both NMPA clinical trial approval and FDA IND clearance (IND# 180170).

8BEBT-706 (GDOC Dual siRNA)
CategorysiRNA Therapeutic (Liver-Targeted Dual siRNA — GDOC Platform)
Description

Lp(a) + PCSK9 dual-target siRNA built on the GDOC platform in preclinical development for atherosclerotic cardiovascular disease (ASCVD) risk reduction.

9BEBT-720 (GDOC Dual siRNA)
CategorysiRNA Therapeutic (Liver-Targeted Dual siRNA — GDOC Platform)
Description

CIDEB + HSD17B13 dual-target siRNA built on the GDOC platform in preclinical development for MASH (metabolic dysfunction-associated steatohepatitis).

10BEBT-758 (POC-Nervous System)
CategoryOligonucleotide Conjugate Therapeutic (POC-Nervous System Platform)
Description

Peptide-oligonucleotide conjugate targeting SNCA in preclinical development for the treatment of Parkinson's disease.

11BEBT-756 (POC-Nervous System)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bebetter Med

Oncology Pharmaceuticalsbebettermed.cn

BeBetter Med is a Guangzhou-based biopharmaceutical company (SSE STAR: 688759) developing first-in-class small molecule and dual siRNA therapeutics across oncology, cardiometabolic, CNS, and kidney diseases, with one approved product (Ifupinostat for r/r DLBCL) and a 14+ candidate pipeline spanning four proprietary technology platforms.

What Bebetter Med does

BeBetter Med (Guangzhou BeBetter Medical Pharmaceutical Co., Ltd.) is a China-headquartered clinical-stage biopharmaceutical company founded in 2012 that designs first-in-class therapeutics across oncology, cardiometabolic disease, CNS, and kidney indications. Its portfolio is organized around four proprietary technology platforms: a Targeted Small Molecule platform that uses dual pharmacophore chemistry to build dual-target inhibitors; a GDOC platform for liver-targeted dual siRNA; a POC-Nervous System platform for CNS and peripheral nervous system delivery via peptide-oligonucleotide conjugates; and a POC-Kidney platform for renal tubular epithelial cell targeting. The most advanced commercial asset is Ifupinostat (BEBT-908), a globally first-in-class HDAC/PI3Kα dual-target inhibitor that received NMPA approval on July 2, 2025 for relapsed/refractory diffuse large B-cell lymphoma and has subsequently been included in the CSCO and Chinese national lymphoma guidelines (2026 edition). The pipeline additionally includes BEBT-209 (highly selective CDK4 inhibitor in seamless Phase IIb/III for mTNBC), BEBT-109 (EGFR exon 20 selective inhibitor in NSCLC), BEBT-701 (AGT/PCSK9 dual siRNA with both NMPA and FDA clearance), BEBT-503 (pan-PPAR agonist for MASH), and preclinical assets spanning Parkinson's, Alzheimer's, gout, and renal anemia.

The company monetizes via two complementary streams: domestic pharmaceutical product sales through hospital and specialty pharmacy channels in China following NMPA approval, and out-licensing or regional partnership arrangements with global pharma counterparties (revenue mechanics governed by milestone payments and royalties under flexible deal structures). Pricing is determined through Chinese government reimbursement and institutional procurement rather than public list pricing. The company went public on the Shanghai Stock Exchange STAR Market on October 28, 2025 under ticker 688759 and operates a wholly-owned US subsidiary, BeBetter Pharma Inc., in Waltham, Massachusetts to drive global clinical development and BD activity. BeBetter Med is presently organized with 51–100 employees and an active commercial team build-out in Beijing, Shanghai, and Guangzhou.

Bebetter Med firmographics

Firmographics
Name
Bebetter Med
Legal name
Guangzhou BeBetter Medical Pharmaceutical Co., Ltd. (广州必贝特医药股份有限公司)
Website
https://bebettermed.cn
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
BeBetter Med is a Guangzhou-based biopharmaceutical company (SSE STAR: 688759) developing first-in-class small molecule and dual siRNA therapeutics across oncology, cardiometabolic, CNS, and kidney diseases, with one approved product (Ifupinostat for r/r DLBCL) and a 14+ candidate pipeline spanning four proprietary technology platforms.
Ownership category
akta.pro rank

Bebetter Med industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • Small molecule drugs
  • Oncology therapeutics
  • SiRNA drug development
  • Dual-target inhibitors
  • Oligonucleotide conjugates

Where Bebetter Med is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Bebetter Med business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sale of approved drugs, including Ifupinostat (BEBT-908, marketed as 贝特琳®) which received NMPA approval in July 2025 for r/r DLBCL treatment
  2. Licensing and Partnership Deals: Revenue from out-licensing proprietary technologies and drug candidates to global pharmaceutical partners for clinical development and commercialization
  3. Strategic Partnerships: Revenue potential from collaborative development arrangements including co-development, option agreements, and regional partnerships for cardiovascular metabolism, oncology, CNS, and kidney disease programs

Distribution channels2 records

Marketing channels5 records

Bebetter Med product offering

Product offering

Core offering

Bebetter Med is a biopharmaceutical company that discovers, develops, and commercializes first-in-class dual-target small molecule drugs and oligonucleotide therapeutics (dual siRNA and peptide-oligonucleotide conjugates) for oncology, cardiovascular-metabolic diseases, CNS, and kidney diseases. The company sells its approved drug Ifupinostat (BEBT-908) for relapsed/refractory DLBCL in China and pursues out-licensing/co-development partnerships for global commercialization of its pipeline assets.

Product overview

BeBetter Med is a biopharmaceutical company (SSE Stock: 688759) specializing in pioneering research and differentiated technology pathways focused on small molecule drugs and oligonucleotide conjugates. The company's portfolio consists of four integrated technology platforms: Targeted Small Molecule Drugs (for oncology and metabolic diseases), GDOC Platform (liver-targeting dual siRNA for cardiovascular metabolic conditions), POC-Nervous System Platform (CNS and peripheral delivery), and POC-Kidney Platform (renal tubular epithelial cell targeting). The pipeline includes 14+ clinical/preclinical candidates across oncology (BEBT-908/Ifupinostat, BEBT-209, BEBT-109), cardiovascular metabolic diseases (BEBT-701, BEBT-706, BEBT-720, BEBT-503, BEBT-809), and kidney/CNS diseases (BEBT-507, BEBT-758, BEBT-756, BEBT-730, BEBT-733, BEBT-738). Ifupinostat (BEBT-908) is the company's first approved drug (NMPA approved July 2025) as a global first-in-class HDAC/PI3Kα dual-target inhibitor for r/r DLBCL.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ifupinostat (BEBT-908 / 贝特琳®) Global first-in-class HDAC/PI3Kα dual-target small molecule inhibitor approved in China for adult patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) who have received at least two prior lines of systemic therapy. Also in clinical development in combination with CHOP for peripheral T-cell lymphoma (PTCL). Reported 3L+ ORR 54.6% and 2L+ ORR 76.2% with favorable safety.
  • BEBT-209 Highly selective CDK4 inhibitor (CDK4 activity ~6x higher than CDK6) in Phase IIb/III seamless pivotal design for metastatic triple-negative breast cancer (mTNBC) and HR+/HER2- advanced breast cancer. Reported 2-3L ORR 37.5% and median PFS of 6.8 months with manageable safety in mTNBC.
  • BEBT-109 Selective small molecule EGFR inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC). Phase Ib/II data presented at ESMO Asia 2025 showed 2L+ ORR 38.5% and median PFS of 8.9 months.
  • BEBT-503 Pan-PPAR agonist small molecule that completed Phase I clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and diabetes.
  • BEBT-809 Potential first-in-class 20-HETE/GPR75 dual-target small molecule inhibitor in preclinical stage for obesity treatment, designed to preserve muscle mass.
  • BEBT-507 Liver-targeted single siRNA therapeutic targeting TMPRSS6 in Phase I clinical development for the treatment of polycythemia vera (PV).
  • BEBT-701 (GDOC Dual siRNA) Global first-in-class AGT/PCSK9 dual-target siRNA drug built on the GDOC platform in Phase I/II clinical development for the treatment of hypertension and hyperlipidemia. Received both NMPA clinical trial approval and FDA IND clearance (IND# 180170).
  • BEBT-706 (GDOC Dual siRNA) Lp(a) + PCSK9 dual-target siRNA built on the GDOC platform in preclinical development for atherosclerotic cardiovascular disease (ASCVD) risk reduction.
  • BEBT-720 (GDOC Dual siRNA) CIDEB + HSD17B13 dual-target siRNA built on the GDOC platform in preclinical development for MASH (metabolic dysfunction-associated steatohepatitis).
  • BEBT-758 (POC-Nervous System) Peptide-oligonucleotide conjugate targeting SNCA in preclinical development for the treatment of Parkinson's disease.
  • BEBT-756 (POC-Nervous System)

Quantifiable outcome

  • Ifupinostat (BEBT-908) achieved 54.6% ORR in 3rd line+ and 76.2% ORR in 2nd line+ r/r DLBCL patients
  • +3 more outcomes

Companies that use Bebetter Med

Customer profile

Segments1 record

Ideal customer profiles2 records

Bebetter Med technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Bebetter Med partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Bebetter Med competitors and assessment

Company assessment

Market position

Competitive moat3 records

Customer concentration

Bebetter Med social profiles

Digital presence

Bebetter Med financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bebetter Med leadership team

Management profile

Number of profiles

Bebetter Med subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Bebetter Med funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bebetter Med M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bebetter Med

What does Bebetter Med do?

Bebetter Med is a biopharmaceutical company that discovers, develops, and commercializes first-in-class dual-target small molecule drugs and oligonucleotide therapeutics (dual siRNA and peptide-oligonucleotide conjugates) for oncology, cardiovascular-metabolic diseases, CNS, and kidney diseases. The company sells its approved drug Ifupinostat (BEBT-908) for relapsed/refractory DLBCL in China and pursues out-licensing/co-development partnerships for global commercialization of its pipeline assets.

Is Bebetter Med a public or private company?

Bebetter Med is a public company. It is classified as public and is currently operating.

When was Bebetter Med founded?

Bebetter Med was founded in 2012. It employs 1 to 10 people.

Where is Bebetter Med based?

Bebetter Med is headquartered in Waltham, United States, in the North America region.

How does Bebetter Med make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Deals and strategic Partnerships.

Does Bebetter Med have an API?

No public API is recorded for Bebetter Med.

What industry is Bebetter Med in?

Bebetter Med's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAADAB, siRNA Therapeutics (gene silencing). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LarepublicaAprobación de medicina contra el cáncer en China superaría a la de EE.UU.According to a study published in Health Affairs by researchers from the University of Pennsylvania and Friends of Cancer Research, China's National Medical Products Administration approved 94 new cancer drugs between 2020 and 2025, surpassing the 87 approved by the US FDA. China began outpacing the US in cancer drug approvals starting in 2023 and continued through 2025, despite the US still leading in first-in-class drugs (30 of 36) and reviewing applications 117 days faster on average. Three Chinese companies—BeBetter Med, Lepu Biopharma, and Chia Tai Tianqing Pharmaceutical Group (a subsidiary of Sino Biopharmaceutical)—developed pioneering cancer treatments that received approval, signaling China's rapid advancement in biopharmaceutical innovation from generic manufacturing to novel drug development.openPR.comEGFR Non Small Cell Lung Cancer Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Bridge Biotherapeutics, Sichuan Kelun Pharms, BeBetter Med, Avistone BiotechDelveInsight's 2026 EGFR Non Small Cell Lung Cancer Pipeline report summarizes the clinical development landscape for EGFR-targeted NSCLC therapies, covering approximately 30+ pipeline candidates from pre-clinical to late-stage development. Key recent milestones include the FDA's acceptance of Summit Therapeutics' BLA for ivonescimab (PDUFA date November 14, 2026), accelerated approval of Dato-DXd in June 2025, and Johnson & Johnson's positive overall survival data from the MARIPOSA study showing improved outcomes versus osimertinib. The report identifies companies including AstraZeneca, Johnson & Johnson, and Summit Therapeutics as primary developers alongside 20+ other firms advancing therapies such as BBT-207, SKB264, and DZD9008.